



## Joint Working Executive Summary

Published on [www.bayer.co.uk](http://www.bayer.co.uk)

<b>Project title</b>	Collaborative Working to Reduce Strokes Caused by Atrial Fibrillation (AF)
<b>Project partners</b>	<ul style="list-style-type: none"><li>• Innovation Agency, Academic Health Science Network for the North West Coast</li><li>• Bayer plc</li></ul>
<b>Project summary</b>	<p>Coordinating organisations to work effectively with patients to prevent AF related strokes is a key priority for the Innovation Agency.</p> <p>The Innovation Agency in partnership with Bayer through a joint working agreement wish to drive adoption of best practice from successful work across the National AHSN network. We will draw on the projects, tools and techniques already developed and evaluated in other parts of the country to effectively deliver an AF stroke prevention programme in primary care.</p> <p>The main focus of this initiative is to implement an AF focused Quality Improvement (QI) initiative in GP practices. This will support practices in identifying, reviewing and managing patients which will lead to the implementation of sustainable change in the prevention of AF related stroke.</p>
<b>Expected benefits to patients, the NHS and Bayer</b>	<p><b><u>Patients</u></b></p> <ul style="list-style-type: none"><li>• Reduce AF related stroke risk by improving anti-coagulation</li><li>• Reduce number of AF related strokes</li><li>• Increase the numbers of patients with AF who are managed in accordance with NICE guidance</li></ul> <p><b><u>NHS</u></b></p> <ul style="list-style-type: none"><li>• Improved management of patients at risk of stroke in line with NICE guidance</li><li>• CCGs/practices better understand how to apply the quality improvement methodology and apply the methodology to other disease areas</li><li>• Learning from using QI methodology</li></ul> <p><b><u>Bayer</u></b></p> <ul style="list-style-type: none"><li>• Increase number of patients appropriately anti-coagulated which may include uptake of NOACs in line with national guidelines, which may include rivaroxaban</li><li>• A partnership which tests implementation of QI methodology</li></ul>
<b>Start date</b>	March 2017

Date of Preparation: January 2019

CF Document Number: PP-OTH-GB-0032